MA45090A - Compositions anticancéreuses - Google Patents

Compositions anticancéreuses

Info

Publication number
MA45090A
MA45090A MA045090A MA45090A MA45090A MA 45090 A MA45090 A MA 45090A MA 045090 A MA045090 A MA 045090A MA 45090 A MA45090 A MA 45090A MA 45090 A MA45090 A MA 45090A
Authority
MA
Morocco
Prior art keywords
cancer compositions
cancer
compositions
Prior art date
Application number
MA045090A
Other languages
English (en)
French (fr)
Inventor
Johny Bertels
Jurgen Mensch
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56148120&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA45090(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of MA45090A publication Critical patent/MA45090A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA045090A 2016-06-03 2017-05-16 Compositions anticancéreuses MA45090A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16172968 2016-06-03

Publications (1)

Publication Number Publication Date
MA45090A true MA45090A (fr) 2021-04-28

Family

ID=56148120

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045090A MA45090A (fr) 2016-06-03 2017-05-16 Compositions anticancéreuses

Country Status (24)

Country Link
US (1) US20190216829A1 (enExample)
EP (1) EP3463377A1 (enExample)
JP (1) JP2019517497A (enExample)
KR (1) KR20190015314A (enExample)
CN (1) CN109219437A (enExample)
AR (1) AR108489A1 (enExample)
AU (1) AU2017275396A1 (enExample)
BR (1) BR112018074965A2 (enExample)
CA (1) CA3024872A1 (enExample)
CL (1) CL2018003403A1 (enExample)
CO (1) CO2018012857A2 (enExample)
CR (1) CR20180600A (enExample)
EA (1) EA201892828A1 (enExample)
IL (1) IL263157A (enExample)
MA (1) MA45090A (enExample)
MX (1) MX2018014846A (enExample)
NI (1) NI201800127A (enExample)
PE (1) PE20181925A1 (enExample)
PH (1) PH12018502334A1 (enExample)
SG (1) SG11201809680QA (enExample)
TN (1) TN2018000366A1 (enExample)
TW (1) TW201808287A (enExample)
UA (1) UA124154C2 (enExample)
WO (1) WO2017209939A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66323B1 (sr) 2014-12-05 2025-01-31 Aragon Pharmaceuticals Inc Sastavi protiv raka
MA41111B1 (fr) 2014-12-05 2021-09-30 Aragon Pharmaceuticals Inc Compositions anticancéreuses
CZ2016573A3 (cs) 2016-09-16 2018-03-28 Zentiva, K.S. Pevná formulace abirateronu acetátu vyráběná technologií fluidní granulace
CN109125276A (zh) * 2017-06-19 2019-01-04 齐鲁制药有限公司 一种醋酸阿比特龙片剂的药物组合物及其制备方法
US20200397756A1 (en) * 2018-02-09 2020-12-24 Kashiv Biosciences, Llc A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens
EP3784218A1 (en) 2018-04-26 2021-03-03 Synthon B.V. Tablet compositions comprising abiraterone acetate
EP3999040A4 (en) * 2019-07-15 2023-07-19 Shilpa Medicare Limited DISPERSABLE TABLETS OF ABIRATERONACETATE
JP2022091129A (ja) * 2020-12-08 2022-06-20 東和薬品株式会社 組成物ならびにその製造方法および用途
WO2025174375A1 (en) * 2024-02-15 2025-08-21 Aragon Pharmaceuticals, Inc. Anticancer compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2265624B (en) 1992-03-31 1995-04-19 British Tech Group 17-substituted steroids useful in cancer treatment
CN113135892A (zh) 2012-06-07 2021-07-20 阿拉贡药品公司 雄激素受体调节剂的晶形
TWI686212B (zh) * 2013-03-15 2020-03-01 阿聯商太陽法瑪全球有限公司 醋酸阿比特龍配方
CN112402360A (zh) * 2014-02-05 2021-02-26 斯洛文尼亚莱柯制药股份有限公司 雄激素受体拮抗剂的固体药物组合物
TWI718102B (zh) * 2014-08-08 2021-02-11 日商中外製藥股份有限公司 4環性化合物的非晶質體

Also Published As

Publication number Publication date
CA3024872A1 (en) 2017-12-07
TN2018000366A1 (en) 2020-06-15
US20190216829A1 (en) 2019-07-18
UA124154C2 (uk) 2021-07-28
CN109219437A (zh) 2019-01-15
PE20181925A1 (es) 2018-12-11
JP2019517497A (ja) 2019-06-24
NI201800127A (es) 2019-03-29
KR20190015314A (ko) 2019-02-13
WO2017209939A1 (en) 2017-12-07
CL2018003403A1 (es) 2019-02-01
EA201892828A1 (ru) 2019-05-31
IL263157A (en) 2018-12-31
MX2018014846A (es) 2019-03-14
SG11201809680QA (en) 2018-11-29
CO2018012857A2 (es) 2018-12-14
BR112018074965A2 (pt) 2019-03-12
TW201808287A (zh) 2018-03-16
EP3463377A1 (en) 2019-04-10
CR20180600A (es) 2019-07-11
AR108489A1 (es) 2018-08-29
PH12018502334A1 (en) 2019-07-29
AU2017275396A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
EP3534968A4 (en) ANTI-BCMA T CAR LYMPHOCYTE COMPOSITIONS
EP3563835A4 (en) NEW EXOSOME-BASED ANTI-CANCER AGENT
DK3361870T3 (da) Fungicidsammensætninger
MA41107A (fr) Compositions anti-cancéreuses
EP3493800A4 (en) CANNABIS
DK3529248T3 (da) Farmaceutiske sammensætninger
LT3226842T (lt) Priešvėžinės kompozicijos
DK3542812T3 (da) Glycopeptidsammensætninger
EP3339331A4 (en) COMPOSITION
LT3226843T (lt) Priešvėžinės kompozicijos
DK3250182T3 (da) Dispergible sammensætninger
DK3334726T3 (da) Plinabulinsammensætninger
MA45090A (fr) Compositions anticancéreuses
DK3528902T3 (da) Ringegelsammensætning
EP3480228A4 (en) COMPOSITION
DK3322295T3 (da) Sammensætning
DK3316857T3 (da) Multifasiske sammensætninger
DK3528791T3 (da) Dispergible sammensætninger
EP3556804A4 (en) COMPOSITION
EP3548044A4 (en) ARSENIC COMPOSITIONS
DK3393254T3 (da) Sammensætning
EP3443034C0 (en) COMPOSITION
DK3416502T3 (da) Glykæmisk-reducerende sammensætning
DK3200827T3 (da) Sammensætninger
EP3612172C0 (en) ANTICANCER COMPOUNDS